Ricardo Adrian Nugraha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ricardo Adrian Nugraha has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
- Budi Susetyo Pikir
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya 60132, Indonesia
19 shared publications - Andrianto Andrianto
Department of Cardiology and Vascular Medicine, Dr. Soetomo General Academic Hospital, Surabaya, East Java, Indonesia
14 shared publications - Yudi Her Oktaviono
Universitas Airlangga
12 shared publications - Firas Farisi Alkaff
University Medical Center Groningen
10 shared publications - Mochamad Yusuf Alsagaff
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia Department of Cardiology and Vascular Medicine, Universitas Airlangga Hospital, Surabaya, Indonesia
9 shared publications - Bayu Lestari
Division of Cardiovascular Sciences, University of Manchester, Manchester M13 9PL, UK
8 shared publications
Latest Publications
- 13 July 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (3) , 32-41
A systematic review and meta-analysis of drug-coated balloons versus drug-eluting stents in de novo and in-stent restenosis coronary bifurcation lesions
Background: Coronary bifurcation lesions are notoriously difficult to treat percutaneously and may require advanced techniques. Drug-eluting balloons (DCBs) have several advantages over drug-eluting stents (DESs), including the ability to maintain arterial physiology, reduce the risk of stent thrombosis, and eliminate the need for permanent metal implants. However, it remains uncertain which treatment will work best. Objective: This study evaluated DCBs and DESs in coronary bifurcation lesions using subgroup analyses based on lesion type and location. Methods: We searched scientific databases for relevant publications up until May 31, 2025. In order to synthesise the results, a random-effects model was employed. To determine the possibility of bias, the ROBINS-I was utilized, and to measure the level of heterogeneity across the studies, the I³ statistic was used. Results were analyzed clinically and angiographically. This subgroup analysis focused on the position of the bifurcation and the kind of lesion (new, internal, or all sites). Result: Eleven research were deemed eligible for inclusion. There was a trend toward fewer major adverse cardiac events (MACE) with DCB compared to DES in the whole cohort, however the trend was not statistically significant (OR0.77, 95% CI0.58-1.02; p=0.07; I²=0%). Both major adverse cardiac events (MACE) and target lesion revascularization (TLR) were significantly reduced in de novo bifurcations when DCB was used (OR0.61, 95% CI 0.41-0.89; p=0.01). Myocardial infarction, target vessel revascularization, in-stent thrombosis, and cardiac mortality were not significantly different among groups. Both the early and late lumen loss and gain seen on angiograms were within the normal range. Conclusion: In de novo bifurcation lesions, DCB demonstrates reduced MACE and TLR versus DES, supporting its role as a stent-free alternative. Randomized controlled trials with greater sample sizes and prolonged follow-up are warranted. Keyword : Coronary Bifurcation; Drug-Coated Balloons; Drug-Eluting Stents; In-Stent Restenosis; Percutaneous Coronary Intervention.
- 13 July 2026
- Published by Brawijaya University in Heart Science Journal
- Vol. 7 (3) , 32-41
A systematic review and meta-analysis of drug-coated balloons versus drug-eluting stents in de novo and in-stent restenosis coronary bifurcation lesions
Background: Coronary bifurcation lesions are notoriously difficult to treat percutaneously and may require advanced techniques. Drug-eluting balloons (DCBs) have several advantages over drug-eluting stents (DESs), including the ability to maintain arterial physiology, reduce the risk of stent thrombosis, and eliminate the need for permanent metal implants. However, it remains uncertain which treatment will work best. Objective: This study evaluated DCBs and DESs in coronary bifurcation lesions using subgroup analyses based on lesion type and location. Methods: We searched scientific databases for relevant publications up until May 31, 2025. In order to synthesise the results, a random-effects model was employed. To determine the possibility of bias, the ROBINS-I was utilized, and to measure the level of heterogeneity across the studies, the I³ statistic was used. Results were analyzed clinically and angiographically. This subgroup analysis focused on the position of the bifurcation and the kind of lesion (new, internal, or all sites). Result: Eleven research were deemed eligible for inclusion. There was a trend toward fewer major adverse cardiac events (MACE) with DCB compared to DES in the whole cohort, however the trend was not statistically significant (OR0.77, 95% CI0.58-1.02; p=0.07; I²=0%). Both major adverse cardiac events (MACE) and target lesion revascularization (TLR) were significantly reduced in de novo bifurcations when DCB was used (OR0.61, 95% CI 0.41-0.89; p=0.01). Myocardial infarction, target vessel revascularization, in-stent thrombosis, and cardiac mortality were not significantly different among groups. Both the early and late lumen loss and gain seen on angiograms were within the normal range. Conclusion: In de novo bifurcation lesions, DCB demonstrates reduced MACE and TLR versus DES, supporting its role as a stent-free alternative. Randomized controlled trials with greater sample sizes and prolonged follow-up are warranted. Keyword : Coronary Bifurcation; Drug-Coated Balloons; Drug-Eluting Stents; In-Stent Restenosis; Percutaneous Coronary Intervention.
- Open Access
- 4 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1716
RURUS SURYAWAN Score: A Novel Scoring System to Predict 30-Day Mortality for Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Background/Objectives: It is essential to identify acute myocardial infarction patients with greater risk of deterioration following primary percutaneous coronary intervention. Due to an inconsistent result about predictors of 30-day outcomes regarding scoring systems for the first episode of acute myocardial infarction, the objective of this study is to develop novel scoring systems to predict 30-day mortality among patients with a first episode of acute myocardial infarction who underwent primary percutaneous coronary intervention. Methods: This retrospective study was conducted with total sampling for all patients with first-time acute myocardial infarction who underwent primary percutaneous coronary intervention between 2021 and 2024 at Dr. Soetomo Hospital, Indonesia. We performed a total sampling and collected 1714 patients, of which 1535 patients were included. Our primary outcomes included 30-day mortality. Results: The analysis included 1535 patients: 926 in the derivation set and 609 in the validation set. In our study, the 30-day mortality rate was 20.7%. Multivariate logistic regression analysis was used to build prediction models in the derivation group and then validated in the validation cohort. The area under the ROC curve of the RURUS SURYAWAN score to predict 30-day mortality was 0.944 (0.906–0.972) in the derivation set and 0.959 (0.921–0.983) in the validation set, with 94.6% sensitivity and 97.3% specificity (p < 0.001). Conclusions: After adjusting for potential confounders, we developed RURUS SURYAWAN, a novel scoring system to identify predictors of 30-day mortality among acute myocardial infarction before primary percutaneous coronary intervention.
- 4 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1716
Open AccessRURUS SURYAWAN Score: A Novel Scoring System to Predict 30-Day Mortality for Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Background/Objectives: It is essential to identify acute myocardial infarction patients with greater risk of deterioration following primary percutaneous coronary intervention. Due to an inconsistent result about predictors of 30-day outcomes regarding scoring systems for the first episode of acute myocardial infarction, the objective of this study is to develop novel scoring systems to predict 30-day mortality among patients with a first episode of acute myocardial infarction who underwent primary percutaneous coronary intervention. Methods: This retrospective study was conducted with total sampling for all patients with first-time acute myocardial infarction who underwent primary percutaneous coronary intervention between 2021 and 2024 at Dr. Soetomo Hospital, Indonesia. We performed a total sampling and collected 1714 patients, of which 1535 patients were included. Our primary outcomes included 30-day mortality. Results: The analysis included 1535 patients: 926 in the derivation set and 609 in the validation set. In our study, the 30-day mortality rate was 20.7%. Multivariate logistic regression analysis was used to build prediction models in the derivation group and then validated in the validation cohort. The area under the ROC curve of the RURUS SURYAWAN score to predict 30-day mortality was 0.944 (0.906–0.972) in the derivation set and 0.959 (0.921–0.983) in the validation set, with 94.6% sensitivity and 97.3% specificity (p < 0.001). Conclusions: After adjusting for potential confounders, we developed RURUS SURYAWAN, a novel scoring system to identify predictors of 30-day mortality among acute myocardial infarction before primary percutaneous coronary intervention.
- Open Access
- 3 March 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (3) , 367
The Emerging Role of Colchicine to Inhibit NOD-like Receptor Family, Pyrin Domain Containing 3 Inflammasome and Interleukin-1β Expression in In Vitro Models
While the beneficial effects of colchicine on inflammation and infarcted myocardium have been documented, its impact on cardiac fibroblast activation in the context of myocardial infarction (MI) remains unknown. This study aimed to investigate the effect of colchicine on the regulation of NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome activation and Interleukin-1β (IL-1β) expression in fibroblasts. 3T3 fibroblasts were exposed to 600 μM CoCl2 for 24 h to simulate hypoxia, with normoxic cells as controls. Colchicine (1 μM) was administered for 24 h. ASC-NLRP3 colocalization and IL-1β expression were evaluated using immunofluorescence and flow cytometry, respectively. Data were analyzed using t-tests and one-way ANOVA with post hoc tests. Hypoxia treatment significantly induced apoptosis-associated speck-like protein containing a CARD (ASC)-NLRP3 colocalization (p < 0.05). Colchicine treatment of hypoxic 3T3 cells reduced ASC-NLRP3 colocalization, although this reduction was not statistically significant. Additionally, IL-1β expression was significantly inhibited in colchicine-treated hypoxic 3T3 cells compared to those treated with placebo (p < 0.05). The findings of this study indicate that colchicine treatment inhibits the activation of the NLRP3 inflammasome by disrupting the colocalization of ASC and NLRP3, thereby reducing IL-1β expression in CoCl2-treated 3T3 cells.
- 3 March 2025
- Published by MDPI AG in Biomolecules
- Vol. 15 (3) , 367
Open AccessThe Emerging Role of Colchicine to Inhibit NOD-like Receptor Family, Pyrin Domain Containing 3 Inflammasome and Interleukin-1β Expression in In Vitro Models
While the beneficial effects of colchicine on inflammation and infarcted myocardium have been documented, its impact on cardiac fibroblast activation in the context of myocardial infarction (MI) remains unknown. This study aimed to investigate the effect of colchicine on the regulation of NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome activation and Interleukin-1β (IL-1β) expression in fibroblasts. 3T3 fibroblasts were exposed to 600 μM CoCl2 for 24 h to simulate hypoxia, with normoxic cells as controls. Colchicine (1 μM) was administered for 24 h. ASC-NLRP3 colocalization and IL-1β expression were evaluated using immunofluorescence and flow cytometry, respectively. Data were analyzed using t-tests and one-way ANOVA with post hoc tests. Hypoxia treatment significantly induced apoptosis-associated speck-like protein containing a CARD (ASC)-NLRP3 colocalization (p < 0.05). Colchicine treatment of hypoxic 3T3 cells reduced ASC-NLRP3 colocalization, although this reduction was not statistically significant. Additionally, IL-1β expression was significantly inhibited in colchicine-treated hypoxic 3T3 cells compared to those treated with placebo (p < 0.05). The findings of this study indicate that colchicine treatment inhibits the activation of the NLRP3 inflammasome by disrupting the colocalization of ASC and NLRP3, thereby reducing IL-1β expression in CoCl2-treated 3T3 cells.
- Open Access
- 18 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1347
Efficacy of Colchicine in Reducing NT-proBNP, Caspase-1, TGF-β, and Galectin-3 Expression and Improving Echocardiography Parameters in Acute Myocardial Infarction: A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
Background: Caspase-1 (reflects NOD-like receptor protein 3 inflammasome activity), transforming growth factor-β (TGF-β), and Galectin-3 play significant roles in post-AMI fibrosis and inflammation. Recently, colchicine was shown to dampen inflammation after AMI; however, its direct benefit remains controversial. Objectives: This study aimed to analyze the benefit of colchicine in reducing NT-proBNP, Caspase-1, TGF-β,and Galectin-3 expression and improving systolic–diastolic echocardiography parameters among AMI patients. Methods: A double-blinded, placebo-controlled, randomized, multicenter clinical trial was conducted at three hospitals in East Java, Indonesia: Dr. Saiful Anwar Hospital Malang, Dr. Soebandi Hospital Jember, and Dr. Iskak Hospital Tulungagung, between 1 June and 31 December 2023. A total of 161 eligible AMI subjects were randomly allocated 1:1 to colchicine (0.5 mg daily) or standard treatment for 30 days. Caspase-1, TGF-β, and Galectin-3 were tested on day 1 and day 5 by ELISA, while NT-proBNP was tested on days 5 and 30. Transthoracic echocardiography was also performed on day 5 and day 30. Results: By day 30, no significant improvements in systolic–diastolic echocardiography parameters had been shown in the colchicine group. However, colchicine reduced the level of NT-proBNP on day 30 more than placebo (ΔNT-proBNP: −73.74 ± 87.53 vs. −75.75 ± 12.44 pg/mL; p < 0.001). Moreover, colchicine lowered the level of Caspase-1 expression on day 5 and the levels of TGF-β and Galectin-3 expression on day 1. Conclusions: Colchicine can reduce NT-proBNP, Caspase-1, TGF-β, and Galectin-3 expression significantly among AMI patients. Colchicine administration was capable of reducing post-AMI inflammation, ventricular dysfunction, and heart failure but did not improve systolic–diastolic echocardiography parameters (ClinicalTrials.gov identifier: NCT06426537).
- 18 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1347
Open AccessEfficacy of Colchicine in Reducing NT-proBNP, Caspase-1, TGF-β, and Galectin-3 Expression and Improving Echocardiography Parameters in Acute Myocardial Infarction: A Multi-Center, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
Background: Caspase-1 (reflects NOD-like receptor protein 3 inflammasome activity), transforming growth factor-β (TGF-β), and Galectin-3 play significant roles in post-AMI fibrosis and inflammation. Recently, colchicine was shown to dampen inflammation after AMI; however, its direct benefit remains controversial. Objectives: This study aimed to analyze the benefit of colchicine in reducing NT-proBNP, Caspase-1, TGF-β,and Galectin-3 expression and improving systolic–diastolic echocardiography parameters among AMI patients. Methods: A double-blinded, placebo-controlled, randomized, multicenter clinical trial was conducted at three hospitals in East Java, Indonesia: Dr. Saiful Anwar Hospital Malang, Dr. Soebandi Hospital Jember, and Dr. Iskak Hospital Tulungagung, between 1 June and 31 December 2023. A total of 161 eligible AMI subjects were randomly allocated 1:1 to colchicine (0.5 mg daily) or standard treatment for 30 days. Caspase-1, TGF-β, and Galectin-3 were tested on day 1 and day 5 by ELISA, while NT-proBNP was tested on days 5 and 30. Transthoracic echocardiography was also performed on day 5 and day 30. Results: By day 30, no significant improvements in systolic–diastolic echocardiography parameters had been shown in the colchicine group. However, colchicine reduced the level of NT-proBNP on day 30 more than placebo (ΔNT-proBNP: −73.74 ± 87.53 vs. −75.75 ± 12.44 pg/mL; p < 0.001). Moreover, colchicine lowered the level of Caspase-1 expression on day 5 and the levels of TGF-β and Galectin-3 expression on day 1. Conclusions: Colchicine can reduce NT-proBNP, Caspase-1, TGF-β, and Galectin-3 expression significantly among AMI patients. Colchicine administration was capable of reducing post-AMI inflammation, ventricular dysfunction, and heart failure but did not improve systolic–diastolic echocardiography parameters (ClinicalTrials.gov identifier: NCT06426537).
- Open Access
- 29 January 2025
- Published by MDPI AG in Preprints.org
The Emerging Role of Colchicine To Inhibit NLRP3 Inflammasome and IL-1β Expression in In Vivo Models
While the beneficial effects of colchicine on inflammation and infarcted myocardium have been documented, its impact on cardiac fibroblast activation in the context of MI remains unknown. This study aimed to investigate the effect of colchicine on the regulation of NLRP3 inflammasome activation and IL-1β expression in fibroblasts. The 3T3 fibroblasts were exposed to 600 μM CoCl2 for 24 hours to simulate hypoxia, with normoxic cells as controls. Colchicine (1 μM) was administered for 24 hours. ASC-NLRP3 colocalization and IL-1β expression were evaluated using immunofluorescence and flow cytometry, respectively. Data were analyzed using t-tests and one-way ANOVA with post-hoc tests. Hypoxia treatment significantly induced ASC-NLRP3 colocalization (p < 0.05). Colchicine treatment of hypoxic 3T3 cells reduced ASC-NLRP3 colocalization, although this reduction was not statistically significant. Additionally, IL-1β expression was significantly inhibited in colchicine-treated hypoxic 3T3 cells compared to those treated with placebo (p < 0.05). The findings of this study indicate that colchicine treatment inhibits the activation of the NLRP3 inflammasome by disrupting the colocalization of ASC and NLRP3, thereby reducing IL-1β expression in CoCl2-treated 3T3 cells.
- 29 January 2025
- Published by MDPI AG in Preprints.org
Open AccessThe Emerging Role of Colchicine To Inhibit NLRP3 Inflammasome and IL-1β Expression in In Vivo Models
While the beneficial effects of colchicine on inflammation and infarcted myocardium have been documented, its impact on cardiac fibroblast activation in the context of MI remains unknown. This study aimed to investigate the effect of colchicine on the regulation of NLRP3 inflammasome activation and IL-1β expression in fibroblasts. The 3T3 fibroblasts were exposed to 600 μM CoCl2 for 24 hours to simulate hypoxia, with normoxic cells as controls. Colchicine (1 μM) was administered for 24 hours. ASC-NLRP3 colocalization and IL-1β expression were evaluated using immunofluorescence and flow cytometry, respectively. Data were analyzed using t-tests and one-way ANOVA with post-hoc tests. Hypoxia treatment significantly induced ASC-NLRP3 colocalization (p < 0.05). Colchicine treatment of hypoxic 3T3 cells reduced ASC-NLRP3 colocalization, although this reduction was not statistically significant. Additionally, IL-1β expression was significantly inhibited in colchicine-treated hypoxic 3T3 cells compared to those treated with placebo (p < 0.05). The findings of this study indicate that colchicine treatment inhibits the activation of the NLRP3 inflammasome by disrupting the colocalization of ASC and NLRP3, thereby reducing IL-1β expression in CoCl2-treated 3T3 cells.
- Open Access
- 21 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 259
Targeting Inflammation with Galectin-3 and PIIINP Modulation Among ST-Segment Elevation Acute Coronary Syndrome Patients Underwent Delayed Percutaneous Coronary Intervention
Background/Objectives: ST-segment elevation acute coronary syndrome (STE-ACS) represents a significant global health challenge, with cardiac remodeling and fibrosis critically affecting recovery after percutaneous coronary intervention (PCI). Colchicine, known for its anti-inflammatory effects, may regulate key fibrotic markers such as Procollagen III N-terminal Propeptide (PIIINP) and Galectin-3. This study assesses colchicine’s effect on these biomarkers in STE-ACS patients undergoing delayed PCI. Methods: In this multicenter, randomized, double-blind trial, we examined colchicine’s impact on Galectin-3 and PIIINP in 164 STE-ACS patients undergoing early or delayed PCI. Patients received colchicine shortly after hospital admission. Biomarker changes were evaluated at 24 h and five days post-treatment using two-way ANOVA. Results: Clinical trials in the early PCI group revealed that Galectin-3 levels decreased significantly on day one (p < 0.01) and further on day five (p < 0.0001), indicating Primary PCI has benefits to inhibition of fibrosis beyond colchicine add-on treatment. But, in the delayed PCI group, Galectin-3 levels significantly increased on day one (p < 0.01), but the decrease observed by day five was not statistically significant. It is related that the benefits of colchicine treatment may exceed PCI implantation in preventing cardiac remodeling. In the delayed PCI group, PIIINP levels showed a significant reduction on day five (p < 0.0001). Conclusions: This Colchicine demonstrates novel efficacy in delayed PCI, with a significant increase in Galectin-3 and a sharp reduction in PIIINP, indicating its ability to control fibrosis. This positions colchicine as a breakthrough therapy for improving outcomes in STE-ACS patients with delayed intervention.
- 21 January 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (2) , 259
Open AccessTargeting Inflammation with Galectin-3 and PIIINP Modulation Among ST-Segment Elevation Acute Coronary Syndrome Patients Underwent Delayed Percutaneous Coronary Intervention
Background/Objectives: ST-segment elevation acute coronary syndrome (STE-ACS) represents a significant global health challenge, with cardiac remodeling and fibrosis critically affecting recovery after percutaneous coronary intervention (PCI). Colchicine, known for its anti-inflammatory effects, may regulate key fibrotic markers such as Procollagen III N-terminal Propeptide (PIIINP) and Galectin-3. This study assesses colchicine’s effect on these biomarkers in STE-ACS patients undergoing delayed PCI. Methods: In this multicenter, randomized, double-blind trial, we examined colchicine’s impact on Galectin-3 and PIIINP in 164 STE-ACS patients undergoing early or delayed PCI. Patients received colchicine shortly after hospital admission. Biomarker changes were evaluated at 24 h and five days post-treatment using two-way ANOVA. Results: Clinical trials in the early PCI group revealed that Galectin-3 levels decreased significantly on day one (p < 0.01) and further on day five (p < 0.0001), indicating Primary PCI has benefits to inhibition of fibrosis beyond colchicine add-on treatment. But, in the delayed PCI group, Galectin-3 levels significantly increased on day one (p < 0.01), but the decrease observed by day five was not statistically significant. It is related that the benefits of colchicine treatment may exceed PCI implantation in preventing cardiac remodeling. In the delayed PCI group, PIIINP levels showed a significant reduction on day five (p < 0.0001). Conclusions: This Colchicine demonstrates novel efficacy in delayed PCI, with a significant increase in Galectin-3 and a sharp reduction in PIIINP, indicating its ability to control fibrosis. This positions colchicine as a breakthrough therapy for improving outcomes in STE-ACS patients with delayed intervention.
- Open Access
- 9 January 2025
- Published by MDPI AG in Preprints.org
Efficacy of Colchicine in Reducing NT-proBNP, Caspase-1, TGF-β, Galectin-3 Expression and Improving Echocardiography Parameter in Acute Myocardial Infarction: A Multi-Centre, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
Background : Caspase-1 (reflects NOD-like receptor protein 3 inflammasomes activity), transforming growth factor-β (TGF-β), and Galectin-3 play significant role in post-AMI fibrosis and inflammation. Recently, colchicine was shown to dampen inflammation after AMI, however, its direct benefit remains controversial. Objectives . This study aimed to analyze the benefit of colchicine in reducing NT-proBNP, Caspase-1, TGF-β and Galectin-3 expression and improving echocardiography parameter among AMI patients. Methods. Double‐blinded, placebo‐controlled, randomized, multicenter clinical trial was conducted at 3 hospitals in East Java Indonesia: Dr. Saiful Anwar Hospital Malang, Dr. Soebandi Hospital Jember, Dr. Iskak Hospital Tulungagung between 1 June-31 December 2023. Total of 161 eligible AMI subjects were randomly allocated 1:1 to colchicine (0.5 mg daily) or standard treatment for 30 days. Caspase-1, TGF-β, and Galectin-3 were tested on day-1 and day-5 by ELISA, whilst NT-proBNP were tested on day 5 and 30. Transthoracic echocardiography were also tested on day 5 and day 30. Results. On day-30, no significant improvement in echocardiography parameter had been shown in colchicine group. However, colchicine reduces level of NT-proBNP on day-30 greater than placebo (ΔNT-proBNP: -273.74 ± 87.53 vs. -75.75 ± 12.44 pg/mL; p<0.001). Moreover, colchicine lower level of Caspase-1 expression on day-5, level of TGF-β and Galectin-3 expression on day-1. Conclusion. Colchicine can reduce NT-proBNP, Caspase-1, TGF-β and Galectin-3 expression significantly among AMI patients but didn’t improve echocardiography parameters (ClinicalTrials.gov identifier: NCT06426537).
- 9 January 2025
- Published by MDPI AG in Preprints.org
Open AccessEfficacy of Colchicine in Reducing NT-proBNP, Caspase-1, TGF-β, Galectin-3 Expression and Improving Echocardiography Parameter in Acute Myocardial Infarction: A Multi-Centre, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial
Background : Caspase-1 (reflects NOD-like receptor protein 3 inflammasomes activity), transforming growth factor-β (TGF-β), and Galectin-3 play significant role in post-AMI fibrosis and inflammation. Recently, colchicine was shown to dampen inflammation after AMI, however, its direct benefit remains controversial. Objectives . This study aimed to analyze the benefit of colchicine in reducing NT-proBNP, Caspase-1, TGF-β and Galectin-3 expression and improving echocardiography parameter among AMI patients. Methods. Double‐blinded, placebo‐controlled, randomized, multicenter clinical trial was conducted at 3 hospitals in East Java Indonesia: Dr. Saiful Anwar Hospital Malang, Dr. Soebandi Hospital Jember, Dr. Iskak Hospital Tulungagung between 1 June-31 December 2023. Total of 161 eligible AMI subjects were randomly allocated 1:1 to colchicine (0.5 mg daily) or standard treatment for 30 days. Caspase-1, TGF-β, and Galectin-3 were tested on day-1 and day-5 by ELISA, whilst NT-proBNP were tested on day 5 and 30. Transthoracic echocardiography were also tested on day 5 and day 30. Results. On day-30, no significant improvement in echocardiography parameter had been shown in colchicine group. However, colchicine reduces level of NT-proBNP on day-30 greater than placebo (ΔNT-proBNP: -273.74 ± 87.53 vs. -75.75 ± 12.44 pg/mL; p<0.001). Moreover, colchicine lower level of Caspase-1 expression on day-5, level of TGF-β and Galectin-3 expression on day-1. Conclusion. Colchicine can reduce NT-proBNP, Caspase-1, TGF-β and Galectin-3 expression significantly among AMI patients but didn’t improve echocardiography parameters (ClinicalTrials.gov identifier: NCT06426537).
- Open Access
- 26 December 2024
- Published by MDPI AG in Preprints.org
RURUS SURYAWAN Score: A Novel Scoring System to Predict 30-Day Mortality for Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Background/Objectives: It is essential to identify acute myocardial infarction patients with greater risk of deterioration following primary percutaneous coronary intervention. Given an inconsistent result about predictors of 30-day outcomes regarding scoring system for first episode of acute myocardial infarction, the objective of this study is to develop novel scoring system to predict 30-day mortality among patients with first episode of acute myocardial infarction underwent primary percutaneous coronary intervention. Methodology. Retrospective study was conducted with total sampling for all patients with first-time acute myocardial infarction underwent primary percutaneous coronary intervention, between 2021 to 2024 at Dr. Soetomo Hospital, Indonesia. We performed a total sampling, collected 1714 patients, in which 1535 patients were included.. Primary outcomes were 30-day mortality. Results. The analysis included 1535 patients: derivation set 926 and validation set 609. In our study, the 30-day mortality was 20.7%. Multivariate logistic regression analysis was used to build prediction models in derivation group, and then validated in validation cohort. Discrimination, calibration and clinical usefulness of the predicting model were assessed using the C-index, calibration plot and decision curve analysis. After pairwise comparison, the best performing model was chosen to build a nomogram according to the regression coefficients. The AUROC was 0.944 (0.906–0.972) in the derivation set and 0.959 (0.921–0.983) in the validation set. Conclusion. After adjusting for potential confounders, we developed RURUS SURYAWAN, a novel scoring system to identify predictor of 30-day mortality among acute myocardial infarction before primary percutaneous coronary intervention.
- 26 December 2024
- Published by MDPI AG in Preprints.org
Open AccessRURUS SURYAWAN Score: A Novel Scoring System to Predict 30-Day Mortality for Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Background/Objectives: It is essential to identify acute myocardial infarction patients with greater risk of deterioration following primary percutaneous coronary intervention. Given an inconsistent result about predictors of 30-day outcomes regarding scoring system for first episode of acute myocardial infarction, the objective of this study is to develop novel scoring system to predict 30-day mortality among patients with first episode of acute myocardial infarction underwent primary percutaneous coronary intervention. Methodology. Retrospective study was conducted with total sampling for all patients with first-time acute myocardial infarction underwent primary percutaneous coronary intervention, between 2021 to 2024 at Dr. Soetomo Hospital, Indonesia. We performed a total sampling, collected 1714 patients, in which 1535 patients were included.. Primary outcomes were 30-day mortality. Results. The analysis included 1535 patients: derivation set 926 and validation set 609. In our study, the 30-day mortality was 20.7%. Multivariate logistic regression analysis was used to build prediction models in derivation group, and then validated in validation cohort. Discrimination, calibration and clinical usefulness of the predicting model were assessed using the C-index, calibration plot and decision curve analysis. After pairwise comparison, the best performing model was chosen to build a nomogram according to the regression coefficients. The AUROC was 0.944 (0.906–0.972) in the derivation set and 0.959 (0.921–0.983) in the validation set. Conclusion. After adjusting for potential confounders, we developed RURUS SURYAWAN, a novel scoring system to identify predictor of 30-day mortality among acute myocardial infarction before primary percutaneous coronary intervention.
- Open Access
- 23 December 2024
- Published by MDPI AG in Preprints.org
Targeting Inflammation with Galectin-3 and PIIINP Modulation among ST-segment Elevation Myocardial Infarction Patients Underwent Delayed Percutaneous Coronary Intervention
Background/Objectives: ST-segment elevation myocardial infarction (STEMI) represents a significant global health challenge, with cardiac remodelling and fibrosis critically affecting recovery after reperfusion therapy. Colchicine, known for its anti-inflammatory effects, has been shown to significantly increase Interleukin-10 (IL-10) levels, particularly in delayed PCI cases, as demonstrated in our previous research. In addition to IL-10, colchicine may regulate key fibrotic markers such as Procollagen III N-terminal Propeptide (PIIINP) and Galectin-3. This study assesses colchicine's effect on these biomarkers, with a focus on its potential benefits in STEMI patients undergoing delayed PCI, where inflammation and fibrosis are more pronounced. Methods: In this multicenter, randomized, double-blind trial, we examined colchicine's impact on Galectin-3 and PIIINP in 164 AMI patients undergoing early or delayed PCI. Patients received colchicine shortly after hospital admission. Biomarker changes were evaluated at 24 hours and five days post-treatment using two-way ANOVA and multiple comparison tests. Results: Clinical trials in patients with STEMI revealed that in the primary PCI group, Galectin-3 levels decreased significantly on day one (p < 0.01) and further on day five (p < 0.0001), indicating Primary PCI has benefit to inhibition of fibrosis beyond colchicine add on treatment. But, in the delayed PCI group, Galectin-3 levels significantly increased on day one (p < 0.01), but the decrease observed by day five was not statistically significant. It related the benefits of colchicine treatment may exceed PCI implantation to prevent cardiac remodelling. Regarding PIIINP, levels significantly decreased in the primary PCI group after five days of colchicine administration (p < 0.0001), indicating reduced fibrosis process. Similarly, in the delayed PCI group, PIIINP levels showed a significant reduction on day five (p < 0.0001). Conclusions: This Colchicine demonstrates novel efficacy in delayed PCI, with a significant increase in Galectin-3 and a sharp reduction in PIIINP, indicating its ability to control fibrosis. This positions colchicine as a breakthrough therapy for improving outcomes in STEMI patients with delayed intervention.
- 23 December 2024
- Published by MDPI AG in Preprints.org
Open AccessTargeting Inflammation with Galectin-3 and PIIINP Modulation among ST-segment Elevation Myocardial Infarction Patients Underwent Delayed Percutaneous Coronary Intervention
Background/Objectives: ST-segment elevation myocardial infarction (STEMI) represents a significant global health challenge, with cardiac remodelling and fibrosis critically affecting recovery after reperfusion therapy. Colchicine, known for its anti-inflammatory effects, has been shown to significantly increase Interleukin-10 (IL-10) levels, particularly in delayed PCI cases, as demonstrated in our previous research. In addition to IL-10, colchicine may regulate key fibrotic markers such as Procollagen III N-terminal Propeptide (PIIINP) and Galectin-3. This study assesses colchicine's effect on these biomarkers, with a focus on its potential benefits in STEMI patients undergoing delayed PCI, where inflammation and fibrosis are more pronounced. Methods: In this multicenter, randomized, double-blind trial, we examined colchicine's impact on Galectin-3 and PIIINP in 164 AMI patients undergoing early or delayed PCI. Patients received colchicine shortly after hospital admission. Biomarker changes were evaluated at 24 hours and five days post-treatment using two-way ANOVA and multiple comparison tests. Results: Clinical trials in patients with STEMI revealed that in the primary PCI group, Galectin-3 levels decreased significantly on day one (p < 0.01) and further on day five (p < 0.0001), indicating Primary PCI has benefit to inhibition of fibrosis beyond colchicine add on treatment. But, in the delayed PCI group, Galectin-3 levels significantly increased on day one (p < 0.01), but the decrease observed by day five was not statistically significant. It related the benefits of colchicine treatment may exceed PCI implantation to prevent cardiac remodelling. Regarding PIIINP, levels significantly decreased in the primary PCI group after five days of colchicine administration (p < 0.0001), indicating reduced fibrosis process. Similarly, in the delayed PCI group, PIIINP levels showed a significant reduction on day five (p < 0.0001). Conclusions: This Colchicine demonstrates novel efficacy in delayed PCI, with a significant increase in Galectin-3 and a sharp reduction in PIIINP, indicating its ability to control fibrosis. This positions colchicine as a breakthrough therapy for improving outcomes in STEMI patients with delayed intervention.
- Open Access
- 14 October 2024
- Published by MDPI AG in Preprints.org
Non-Invasive Measurement for Early Diagnosis of Diastolic Dysfunction among Acute Hypertensive Heart Failure
Objective. This study aimed to determine the correlation of colour M-mode velocity propagation in the assessment of left ventricular diastolic function among acute decompensated heart failure patients with preserved ejection fraction (HFpEF). Materials and Methods. This research is an observational analytical study using a cross–sectional study design conducted from April to June 2022. The subjects of this study were patients diagnosed with acute HFpEF and treated at Dr. Soetomo General Academic Hospital, Surabaya. Patients with heart rhythm disturbances, moderate to severe valvular heart disease, and congenital heart defects were excluded from this study. Patients were measured for diastolic function including mitral valve early mitral inflow velocity (MV E Velocity), mitral peak velocity of early filling (E’) (E' Septal and E' Lateral), left atrial volume index (LAVI), The maximal tricuspid regurgitation velocity (TR V Max), Vp, the ratio of early diastolic mitral inflow velocity to early diastolic mitral annulus velocity (E/E'), the ratio between early and late ventricular filling velocity (E/A) and E/Vp Ratio. N-terminal-pro hormone B-type natriuretic peptide (NT–ProBNP) examination was also performed on study subjects as an additional diagnosis of acute heart failure. Results. There were 33 patients who met the inclusion and exclusion criteria and were included in our study. There were 26 patients (78.8%) with grade I diastolic dysfunction, 4 patients (12.1%) with grade II diastolic dysfunction, and 3 patients (9.1%) with grade III diastolic dysfunction. There is a strong positive correlation between Vp with parameters E' Septal (p = < 0.001; r = 0.636) and E' Lateral (p = < 0.001; r = 0.650). Vp is negatively correlated with the ratio E/E' (p = 0.029; r = –0.37). The PCWP estimate with E/Vp ratio had a strong correlation with the NT–Pro BNP value > 300 pg/ml in acute HFpEF patients (p = < 0.001; r = 0.726) compared to the PCWP estimate with E/E' (p = < 0.001; r = 0.549). Conclusion. There is no correlation between Vp value and degree of diastolic dysfunction in patients with acute HFpEF.
- 14 October 2024
- Published by MDPI AG in Preprints.org
Open AccessNon-Invasive Measurement for Early Diagnosis of Diastolic Dysfunction among Acute Hypertensive Heart Failure
Objective. This study aimed to determine the correlation of colour M-mode velocity propagation in the assessment of left ventricular diastolic function among acute decompensated heart failure patients with preserved ejection fraction (HFpEF). Materials and Methods. This research is an observational analytical study using a cross–sectional study design conducted from April to June 2022. The subjects of this study were patients diagnosed with acute HFpEF and treated at Dr. Soetomo General Academic Hospital, Surabaya. Patients with heart rhythm disturbances, moderate to severe valvular heart disease, and congenital heart defects were excluded from this study. Patients were measured for diastolic function including mitral valve early mitral inflow velocity (MV E Velocity), mitral peak velocity of early filling (E’) (E' Septal and E' Lateral), left atrial volume index (LAVI), The maximal tricuspid regurgitation velocity (TR V Max), Vp, the ratio of early diastolic mitral inflow velocity to early diastolic mitral annulus velocity (E/E'), the ratio between early and late ventricular filling velocity (E/A) and E/Vp Ratio. N-terminal-pro hormone B-type natriuretic peptide (NT–ProBNP) examination was also performed on study subjects as an additional diagnosis of acute heart failure. Results. There were 33 patients who met the inclusion and exclusion criteria and were included in our study. There were 26 patients (78.8%) with grade I diastolic dysfunction, 4 patients (12.1%) with grade II diastolic dysfunction, and 3 patients (9.1%) with grade III diastolic dysfunction. There is a strong positive correlation between Vp with parameters E' Septal (p = < 0.001; r = 0.636) and E' Lateral (p = < 0.001; r = 0.650). Vp is negatively correlated with the ratio E/E' (p = 0.029; r = –0.37). The PCWP estimate with E/Vp ratio had a strong correlation with the NT–Pro BNP value > 300 pg/ml in acute HFpEF patients (p = < 0.001; r = 0.726) compared to the PCWP estimate with E/E' (p = < 0.001; r = 0.549). Conclusion. There is no correlation between Vp value and degree of diastolic dysfunction in patients with acute HFpEF.